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Introduction
Fibrates are synthetic agonists of peroxisome proliferator-activated receptor-α (PPARα), a nuclear receptor also activated by natural ligands like free fatty acids or some eicosanoids.
Activation of PPARα leads to up-regulation of transcription of several genes involved mainly in mitochondrial and peroxisomal ß-oxidation, ketogenesis and gluconeogenesis (Mandard et al., 2004) . Fibrates have been in clinical use as hypolipidemic agents for several decades.
Several studies in rodents and cell culture systems have shown that fibrates, like many other drugs (e.g. phenobarbital, 3-methylcholantrene, polychlorinated biphenyl, tetrachlorobiphenyl, pregnenolone-16 α -carbonitrile or dexamethasone), induce uridine diphosphate-glucuronosyl-transferases (UGTs) (Beetstra et al., 1991; Saito et al., 1991; Barter and Klaassen, 1992a , 1992b , 1994 Visser et al., 1993a Visser et al., , 1993b Viollon-Abadie et al., 2000; Jemnitz et al., 2000; Vansell and Klaassen, 2002) . UGTs, consisting of UGT1 and UGT2
isoforms, are localized in the endoplasmatic reticulum of hepatocytes and extrahepatic tissue and belong to the enzymes of phase II metabolism. With broad and overlapping substrate specifities, the UGT isoenzymes catalyze the glucuronidation of differential functional groups, using UDP-glucuronic acid as the cofactor (Miners and Mackenzie, 1991; Mackenzie et al., 1997) . Thyroid hormones, thyroxine (T 4 ) and triiodothyronine (T 3 ), are substrates of hepatic UGTs, and glucuronidation of these hormones is the main metabolic pathway for deactivating them (Jemnitz et al., 2000) . In rats several of the drugs acting as inducers of microsomal enzymes have been shown to produce hypertrophy and hyperplasia of thyroid follicular cells, most probably through increased deactivation of thyroid hormones by UGTs, leading to a reduction of serum T 4 and possibly T 3 (Beestra et al. 1991; Saito et al. 1991; Klaassen 1992a, 1994) . In mice, in contrast to rats, clofibrate treatment did not alter T 3 -and T 4 -UGT activities and plasma concentrations of thyroid hormones (ViollonAbadie et al. 1999) . These studies show species-specific differences in the effects of clofibrate on hepatic thyroid hormone metabolism, i.e. glucuronidation of thyroid hormones.
This article has not been copyedited and formatted. The final version may differ from this version. In rodents, PPARα agonists not only induce many genes involved in various metabolic pathways such as ß-oxidation, ketogenesis and gluconeogenesis but also cause severe peroxisome proliferation in the liver, hepatomegaly and hepatocarcinogenesis (Peters et al., 2005) . In contrast to rodents, PPARα agonists do not induce peroxisome proliferation or tumor in the liver of many other species, such as guinea pigs, swine, monkeys and humans, although they retain a hypotriglyceridemic effect in these species (Holden and Tugwood, 1999) . In non-proliferating species, expression of PPARα in the liver is much lower and the response of many genes to PPARα activation is weaker than in proliferating species (Cheon et al., 2005) . It is known that PPARα activation can modulate metabolizing enzymes of phase I and II biotransformation (Rushmore and Kong, 2002; Zhou et al., 2005) . Moreover, it has been shown that some UGT isoforms (UGT1A9, UGT2B4) are PPARα target genes (Barbier et al., 2003a; 2003b) . Therefore, non-proliferating species could respond differently from proliferating species to clofibrate with respect to induction of UGTs, i.e. UGTs involved in glucuronidation of thyroid hormones. To our knowledge, the effect of clofibrate on the hepatic thyroid hormone metabolism has not yet been investigated in vivo in a nonproliferating species.
The aim of our study was to investigate the effects of clofibrate treatment on hepatic thyroid hormone metabolism, i.e. activities of T 3 -and T 4 -UGTs in pigs, representing a nonproliferating species. Therefore, as well administration determining hepatic activities of T 3 -and T 4 -UGTs, we also measured plasma concentrations of thyroid hormones, thyroid weights, thyroidal epithelial cell height and follicle lumen diameter and gene expression levels of several thyroidal genes involved in thyroid hormone biosynthesis (TSH receptor, sodium iodide symporter, thyroid peroxidase, dual oxidase 2, thyroglobulin, cathepsin B and type-II iodothyronine deiodinase). We also investigated the effect of clofibrate on mRNA expression of genes involved in thyroid hormone transport (transthyretin, thyroxine-binding globulin and 
Animals and treatments. Eighteen male 8-week-old crossbred [(German Landrace x
Large White) x Pietrain] pigs, bred in the local animal facility, were used. They weighed between 11.0 and 13.5 kg. They were individually housed in a room maintained at 23°C and 50 to 60% relative humidity with light from 0600 to 1800 h. On the day before the start of the experimental feeding period all pigs were weighed and assigned to two groups with body weights of 12.0 ± 1.1 (SD) kg (control group) and 11.9 ± 0.6 (SD) kg (treatment group). Both groups of pigs received a nutritionally adequate diet (National Research Council, 1998) for growing pigs containing (in g/kg) wheat (400), soybean meal (230), wheat bran (150), barley (100), sunflower oil (90) and mineral premix including L-lysine, DL-methionine and Lthreonine (30). This diet contained 14.4 MJ metabolisable energy and 185 g crude protein per
kg. The diet of the treatment group was supplemented with 5 g clofibrate per kg. To standardize feed intake each pig within the experiment received 700 g of the diet daily, which was completely consumed by all animals in the experiment. The clofibrate dosage in the treated pigs was 220 mg/kg body weight/day. The pigs had free access to water via nipple drinking systems. The experimental diets were administered for 28 days. All experimental procedures described followed established guidelines for the care and use of laboratory animals and were approved by the local veterinary office.
This article has not been copyedited and formatted. The final version may differ from this version. included in all PCR reactions for detection of contamination and dilutions of the isolated total RNA corresponding to the cDNA synthesis were used as template in order to exclude impurities due to genomic DNA. A volume of 10 µl per PCR reaction was submitted to agarose gel electrophoresis (1.5%). Ethidium bromide stained gels were digitized for quantification (apparatus and software from Syngene, Cambridge, UK).
Preparation of hepatic microsomes. One g of liver was homogenized in a medium (10 ml) containing 0.25 M sucrose and 0.1 M phosphate buffer (pH 7.4) using a PotterElvehjem homogenizer. Homogenates were centrifuged at 1,000 x g for 10 min at 4°C, and the supernatant was centrifuged at 15,000 x g for 15 min. The microsomal pellet was obtained by centrifugation of the 15,000 g supernatant at 105,000 g for 60 min. Microsomal pellets were suspended in the homogenization medium and the protein concentration was determined with the BCA reagent according to the supplier's protocol using bovine serum albumin as standard.
Enzyme assays. The activity of pNP-UGT in hepatic microsomes was assayed by the method of Thurman et al. (1981) . The assay mixture consisted of 50 mM potassium phosphate buffer (pH 7.4), 0.2 mg bovine serum albumin/ml, 1 mM magnesium chloride, 0.5 mM DTT, 0.5 mg Triton X-100/ml, 0.2 mM pNP, 0.2 mM UDPGA and 0.25 mg microsomal protein/ml. Histology of thyroid gland. Samples of thyroid glands were fixed by immersion in 10% neutral buffered formalin, processed for embedding into paraffin wax and cut into 4 µm sections. For light microscopy the sections were stained with hemalum and eosin. The epithelial cell height was measured using 4 cells per follicle in 100 follicles of each thyroid.
The lumen diameter was measured in 10 sections for 10 follicles per section of each thyroid.
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Analysis of plasma hormones. The plasma concentrations of free and total T 4 and total T 3 were measured with radioimmunoassay kits (MP Biomedicals, Eschwege, Germany).
Statistics. The results were analyzed using Minitab (State College, Pa, USA) statistical software (release 13). Statistical significance of differences between control group and treatment group was evaluated using Student´s t-test. Mean values were considered significantly different for p < 0.05.
Results
Initial and final body weights after an experimental period of 28 days were similar in both groups of pigs (Table 2 ). Animals treated with clofibrate had heavier livers (p < 0.05) and higher concentrations of microsomal protein in the liver (p < 0.05) than control pigs (Table 2) . Relative hepatic mRNA concentration of the PPARα target genes ACO and CPT-1 were higher (p < 0.05) in pigs treated with clofibrate than in control pigs (ACO: 1.39 ± 0.27 vs. 1.00 ± 0.35; CPT-1: 1.60 ± 0.13 vs. 1.00 ± 0.12; means ± SD, n = 9 for each group).
Moreover, concentrations of total and free T 4 and total T 3 in plasma were markedly lower in pigs treated with clofibrate than in control pigs (p < 0.05) while the T 4 /T 3 ratio did not differ between both groups of pigs (Table 2) .
Pigs treated with clofibrate had a higher activity of bilirubin-UGT in the liver than control pigs (1.08 ± 0.05 vs. 0.44 ± 0.02 nmol . min -1 . mg -1 ; means ± SD, n = 9 for each group; p < 0.05). The activity of hepatic pNP-UGT was lower in pigs treated with clofibrate than in control pigs (44 ± 5 vs. 70 ± 8 nmol . min -1 . mg -1 ; means ± SD, n = 9 for each group; p < 0.05). Activities of hepatic T 3 -and T 4 -UGTs were higher in pigs treated with clofibrate than in control pigs (p < 0.05, Figure 1 ). Weights of thyroids, diameter of follicle lumen and thyroid epithelial cell height did not differ between both groups of pigs (Table 3) . Relative mRNA concentrations of TSH receptor, sodium iodide symporter, thyroid peroxidase and cathepsin B were higher in thyroids of pigs treated with clofibrate than in thyroids of control pigs (p < 0.05, Figure 2 ).
mRNA concentration of type-II iodothyronine deiodinase was lower in thyroids of pigs treated with clofibrate than in thyroids of control pigs (p < 0.05); those of dual oxidase 2 and thyroglobulin did not differ between both groups of pigs (Figure 2 ).
Pigs treated with clofibrate had lower hepatic mRNA concentrations of transthyretin, albumin and thyroid hormone receptor α 1 than control pigs (p < 0.05; Table 4 ). Hepatic mRNA concentration of thyroxine-binding globulin tended to be lower in pigs treated with clofibrate compared to control pigs (p < 0.10), while hepatic mRNA concentration of type-I iodothyronine deiodinase did not differ between both groups of pigs.
Discussion
To our knowledge, this is the first study to investigate the effect of clofibrate on the hepatic metabolism of thyroid hormones in the pig. It is well known that pigs are a nonproliferating species, meaning that treatment with PPARα agonist cause no or only weak peroxisome proliferation in the liver. Interestingly, in this study clofibrate treatment caused a significant increase in liver weights of pigs by about 15%. This is in disagreement with a recent study in which pigs did not show significantly increased liver weights after a 1-week treatment with a dose of clofibrate similar to those used in our study (Cheon et al., 2005) . The difference in these results could be due to the longer treatment period in our study compared lower than those observed in rodents treated with clofibrate. In rats and mice, feeding
PPARα agonists increases liver weights by 50% or more and mRNA concentrations of ACO 5-to 10-fold compared with untreated controls (Kawashima et al., 1990; He et al., 2002; Li et al., 2004; Frederiksen et al., 2004) .
Several families of UGT enzymes are expressed in the liver. To study the effect of clofibrate treatment on the induction of microsomal enzymes, we determined the activities of bilirubin-and pNP-UGTs. The finding that clofibrate treatment strongly increases bilirubin-UGT is in accordance with studies in rats and mice (Visser et al., 1993a; Viollon-Abadie et al., 1999) . The finding that clofibrate reduces the activity of pNP-UGT is also in accordance with a study in which clofibrate significantly reduced the activity of pNP-UGT in the liver of Wistar rats (Visser et al., 1993a) . These observations suggest that clofibrate stimulated the microsomal enzyme system in pigs in a similar way as in rats. This study also shows that clofibrate treatment strongly increases the activity of T 3 -and T 4 -UGT in the liver, which in turn leads to a dramatic reduction of plasma T 3 and T 4 concentrations. Increased activity of T 4 -UGT had previously been observed in Wistar rats but not in mice treated with clofibrate (Visser et al., 1993a; Viollon-Abadie et al., 1999) . The increased activity of T 3 -UGT in pigs treated with clofibrate, however, is in strong contrast to rats, where clofibrate treatment did not increase T 3 -UGT activity (Visser et al., 1993a) .
In rats T 4 is accepted as a substrate by hepatic bilirubin-UGTs (UGT1A1) and phenolUGTs (UGT1A6) and it was shown that increased activities of these enzymes were associated with increased glucuronidation of T 4 in the liver (Beetstra et al., 1991; Magdalou et al., 1993; Visser et al., 1993a Visser et al., , 1993b Viollon-Abadie et al., 2000; Vansell and Klaassen, 2002 rats and are involved in T4 conjugation (Jemnitz et al., 2000) . In rat liver glucuronidation of T 3 , unlike glucuronidation of T 4 , is catalyzed by androsterone-UGTs (Beetstra et al., 1991; Visser et al., 1993b) . The increased T 3 -UGT activity in pigs treated with clofibrate could therefore also have been due to an increased activity of androsterone-UGT, although this was UGTs. Nevertheless, the role of PPARα in the regulation of thyroid hormone glucuronidation should be further investigated.
The increased activities of T 3 -and T 4 -UGTs make it highly probable that the markedly reduced plasma concentrations of T 3 and T 4 in pigs treated with clofibrate are mainly due to increased glucuronidation of these hormones in the liver. As most T 3 is generated in peripheral tissues, mainly the liver, by deiodination of T 4 , a reduced T 3 concentration could potentially be due to an inhibition of type-I iodothyronine deiodinase. Indeed, in the study of DeSandro et al., 1991; Saito et al., 1991; Liu et al., 1995) .
As no assay was available for measuring TSH concentration in plasma of the pigs, we determined mRNA concentrations of various genes in the thyroid which are responsive to TSH treatment. The finding that mRNA concentrations of TSH receptor, sodium iodide symporter, thyroid peroxidase and cathepsin B, all genes responsive to TSH, were moderately increased by 40 to 70% suggests that the thyroid was stimulated by the increased plasma concentration of TSH. This suggestion is confirmed by a study which demonstrated that TSH plasma concentrations are increased by microsomal enzyme inducers which stimulate the glucuronidation of T 3 (Klaassen and Hood, 2001 ). Our study further shows that expression levels of dual oxidase 2, an hydrogen peroxide-generating system which constitutes the ratelimiting step of thyroid hormone synthesis, and of thyroglobulin, a protein involved in thyroid hormone synthesis and storage, are not altered by clofibrate treatment.
The finding that thyroid weights, epithelial cells and follicle lumen diameter were not increased by clofibrate was unexpected and suggests that stimulation of the thyroid was moderate, only increasing gene expression of TSH-responsive genes in the thyroid while histological alterations, i.e. increased epithelial cell height, may take longer than four weeks to become evident.
The action of thyroid hormones like T 3 is mediated by thyroid hormone receptors which belong to the family of nuclear hormone receptors. The present study shows that clofibrate treatment reduces gene expression of thyroid hormone receptor α 1 in the liver of rats. This finding agrees with a recent study in which bezafibrate down-regulated thyroid hormone receptors in rat liver (Bonilla et al., 2001) . That study further showed that downThis article has not been copyedited and formatted. The final version may differ from this version. Thyroxine-binding globulin, transthyretin and albumin are the major plasma transport proteins in pigs (Janssen et al., 2002) . These proteins are synthesized in the liver. We found that in our study gene expression of these proteins in the liver was reduced by clofibrate treatment of pigs. In studies by Motojima et al. (1992 Motojima et al. ( , 1997 ) the same effect of clofibrate on expression of transthyretin was observed in rats and several mouse strains, while there was no effect in PPARα-null mice. This suggests that down-regulation of transthyretin expression was induced by PPARα activation. Consequently, down-regulation of transthyretin and possibly also of thyroxine-binding globulin and albumin could be the result of PPARα activation by clofibrate. Our data suggest, although we did not measure concentrations of these proteins in blood, that clofibrate treatment lowers not only concentrations of thyroid hormones in plasma but could also reduce the transport capacity for thyroid hormones.
In conclusion, this study shows for the first time that clofibrate treatment induces a strong activation of T 3 -and T 4 -UGTs in pigs, leading to increased glucuronidation and markedly reduced plasma concentrations of these hormones. These alterations were accompanied by moderately increased mRNA concentrations of various TSH-responsive enzymes in the thyroid gland, reduced hepatic mRNA concentrations of proteins involved in thyroid hormone transport and thyroid hormone receptors. As the pig represents a species that does not respond with peroxisome proliferation to treatment with PPARα agonists the study shows that clofibrate treatment also disrupts the metabolism of thyroid hormones in nonproliferating species.
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